An abbreviated new drug application (ANDA) contains data which is submitted to FDA for the review and potential approval of a generic drug product. Once approved, an applicant may manufacture and market the generic drug product to provide a safe, effective, lower cost alternative to the brand-name drug it references.
COMMON REGULATORY AFFAIRS JOB INTERVIEW QUESTIONS WITH ANSWERS-Updated in 2022!Pristyn Research Solutions
COMMON REGULATORY AFFAIRS
JOB INTERVIEW QUESTIONS WITH
ANSWERS By Pristyn Research-Updated 2022.
A quick Job interview short guide For Pharma and all
Life science jobseekers.
info.pristynresearch.com
www.pristynresearch.com
9028839789 | 8999717656
All Medical | Biotech |Micro |B.Sc., M.Sc.
PAN India DRA companies
list alphabetically
This document contains the mostly asked questions for the job interviews of drug regulatory affairs which will help the candidate ace the interview with ease
Thank me later for this :*)
COMMON REGULATORY AFFAIRS JOB INTERVIEW QUESTIONS WITH ANSWERS-Updated in 2022!Pristyn Research Solutions
COMMON REGULATORY AFFAIRS
JOB INTERVIEW QUESTIONS WITH
ANSWERS By Pristyn Research-Updated 2022.
A quick Job interview short guide For Pharma and all
Life science jobseekers.
info.pristynresearch.com
www.pristynresearch.com
9028839789 | 8999717656
All Medical | Biotech |Micro |B.Sc., M.Sc.
PAN India DRA companies
list alphabetically
This document contains the mostly asked questions for the job interviews of drug regulatory affairs which will help the candidate ace the interview with ease
Thank me later for this :*)
ABBREVIATED NEW DRUG APPLICATION (ANDA),INVESTICATION OF MEDICINAL PRODUCTS D...GOKULAKRISHNAN S
Introduction to ANDA
Regulations applied to ANDA process
Format and content of ANDA
ANDA approval process
Exclusivity
Hatch-Waxman amendments & 180 days exclusivity
Introduction to IMPD
Contents of IMPD
Introduction to IB
Contents of IB
Welcome to our informative slide on the New Drug Application (NDA) - a pivotal milestone in the pharmaceutical world that propels medical innovation to new heights. In this concise presentation, we'll explore the significance of the NDA process and its critical role in bringing life-changing medications to patients in need.
Abbreviated New Drug Application [ANDA]Sagar Savale
An Abbreviated New Drug Application (ANDA) contains data which when submitted to FDA's CDER, Office of Generic Drugs, provides for the review and ultimate approval of a generic drug product.
GLOBAL SUBMISSION OF IND, NDA, ANDA.pdfLokeshThakre6
It's important to note that the specific requirements and processes for INDs, NDAs, and ANDAs may vary between regulatory authorities in different countries. The descriptions provided here are general and based on the common practices in the United States.
ABBREVIATED NEW DRUG APPLICATION (ANDA),INVESTICATION OF MEDICINAL PRODUCTS D...GOKULAKRISHNAN S
Introduction to ANDA
Regulations applied to ANDA process
Format and content of ANDA
ANDA approval process
Exclusivity
Hatch-Waxman amendments & 180 days exclusivity
Introduction to IMPD
Contents of IMPD
Introduction to IB
Contents of IB
Welcome to our informative slide on the New Drug Application (NDA) - a pivotal milestone in the pharmaceutical world that propels medical innovation to new heights. In this concise presentation, we'll explore the significance of the NDA process and its critical role in bringing life-changing medications to patients in need.
Abbreviated New Drug Application [ANDA]Sagar Savale
An Abbreviated New Drug Application (ANDA) contains data which when submitted to FDA's CDER, Office of Generic Drugs, provides for the review and ultimate approval of a generic drug product.
GLOBAL SUBMISSION OF IND, NDA, ANDA.pdfLokeshThakre6
It's important to note that the specific requirements and processes for INDs, NDAs, and ANDAs may vary between regulatory authorities in different countries. The descriptions provided here are general and based on the common practices in the United States.
A pharmacist should never disclose any information which he has acquired during his professional activities to any third party or person unless required by law to do so. He should never betray the confidence which his patrons repose in him or which he has won by virtue of his eminent character and conduct.
Emollient and Rheological Additive.pptxPrachi Pandey
Topical emollients are creams, lotions, or ointments that contain ingredients that soothe and soften the skin. The word emollient means a preparation that softens the skin. Another name for an emollient is a moisturizer.
An Overview of CDSCO Registration. The CDSCO stands for Central Drugs Standard Control Organisation is the NRA or National Regulatory Authority under the Directorate General of Health Services, Government of India, and Ministry of Health and Family Welfare.
My presentation based on the CDSCO certification, as well as the complete description about the CDSCO and DCGI.
An in vitro – in vivo correlation (IVIVC) is defined by the U.S Food and Drug Administration (FDA) as a predictive mathematical model describing the relationship between the in vitro property of an oral dosage form and relevant in vivo response.
The application for Registration and import can be made to the Licensing Authority under the Act i.e. to the Drugs Controller General at CDSCO. Drug and Cosmetic Act 1945: It Contains provisions for classification of drugs under given schedules. Guidelines for the storage,sale,display and prescription of each schedule.
Morphine and Related Drugs including their Derivatives.pdfPrachi Pandey
Morphine is a pain medication of the opiate family that is found naturally in a dark brown, resinous form, from the poppy plant (Papaver somniferum). It can be taken orally, sublingually, via inhalation, the trans-dermal route, inter-anally as well as via injection (both subcutaneously as well as more commonly intravenously.
International Conference on Fostering High Quality Clinical Research for A He...Prachi Pandey
This paper abstract presented as poster on a International Conference, Which Held of 26 November 2023. Organized by NIMS Institute of Pharmacy, NIMS University, Jaipur, Rajasthan , India.
0x01 - Newton's Third Law: Static vs. Dynamic AbusersOWASP Beja
f you offer a service on the web, odds are that someone will abuse it. Be it an API, a SaaS, a PaaS, or even a static website, someone somewhere will try to figure out a way to use it to their own needs. In this talk we'll compare measures that are effective against static attackers and how to battle a dynamic attacker who adapts to your counter-measures.
About the Speaker
===============
Diogo Sousa, Engineering Manager @ Canonical
An opinionated individual with an interest in cryptography and its intersection with secure software development.
This presentation by Morris Kleiner (University of Minnesota), was made during the discussion “Competition and Regulation in Professions and Occupations” held at the Working Party No. 2 on Competition and Regulation on 10 June 2024. More papers and presentations on the topic can be found out at oe.cd/crps.
This presentation was uploaded with the author’s consent.
Have you ever wondered how search works while visiting an e-commerce site, internal website, or searching through other types of online resources? Look no further than this informative session on the ways that taxonomies help end-users navigate the internet! Hear from taxonomists and other information professionals who have first-hand experience creating and working with taxonomies that aid in navigation, search, and discovery across a range of disciplines.
This presentation, created by Syed Faiz ul Hassan, explores the profound influence of media on public perception and behavior. It delves into the evolution of media from oral traditions to modern digital and social media platforms. Key topics include the role of media in information propagation, socialization, crisis awareness, globalization, and education. The presentation also examines media influence through agenda setting, propaganda, and manipulative techniques used by advertisers and marketers. Furthermore, it highlights the impact of surveillance enabled by media technologies on personal behavior and preferences. Through this comprehensive overview, the presentation aims to shed light on how media shapes collective consciousness and public opinion.
Sharpen existing tools or get a new toolbox? Contemporary cluster initiatives...Orkestra
UIIN Conference, Madrid, 27-29 May 2024
James Wilson, Orkestra and Deusto Business School
Emily Wise, Lund University
Madeline Smith, The Glasgow School of Art
Acorn Recovery: Restore IT infra within minutesIP ServerOne
Introducing Acorn Recovery as a Service, a simple, fast, and secure managed disaster recovery (DRaaS) by IP ServerOne. A DR solution that helps restore your IT infra within minutes.
1. GLOBAL SUBMISSION OF
ANDA: REGULATORY
AFFAIRS
Presented by: Prachi Pandey, Rahul Pal
M. Pharm (Pharmaceutics)
NIMS Institute of Pharmacy,
NIMS University Jaipur
2. Abbreviated New Drug Application
An ‘Abbreviated New Drug Application (ANDA)’ is an application for a U.S. generic
drug approval from FDA under section 505(j) for an existing licensed medication or
approved drug.
A generic drug product is one that is comparable to a patented drug product in dosage
form, strength, route of administration, quality, performance characteristics and
intended use.
All approved products, both innovator and generic, are listed in FDA's Approved Drug
Products with Therapeutic Equivalence Evaluations (Orange Book).
The Orange Book name can be attributed to the Halloween holiday. The first print
publication occurred October 1980, and orange was selected since it was almost
Halloween.
3. Generic drug applications are termed "abbreviated" because (in comparison with a New Drug
Application) they are generally not required to include preclinical (animal and in vitro) and
clinical (human) trial data to establish safety and effectiveness. Instead, generic applicants
must scientifically demonstrate that their product is bioequivalent (i.e., performs in the same
manner as the innovator drug).
The generic version must deliver the same amount of active ingredients into a patient's
bloodstream in the same amount of time as the innovator drug.
In cases of topically active drugs, the bioequivalence of a drug can be demonstrated by
comparing drugs dissolution or transdermal drug absorption is compared with the innovator
drug. In cases of systemically active drugs, active drug blood concentration of that drug is
compared with the innovator drug.
4. Hatch-
Waxman Act
Using bioequivalence as the basis for
approving generic copies of drug products
was established by the Drug Price
Competition and Patent Term Restoration Act
of 1984 (Public Law 98-417) , also known as
the Hatch-Waxman Act.
The Drug Price Competition and Patent Term
Restoration Act (Public Law 98-417),
informally known as the Hatch-Waxman Act,
established the modern system of
government generic drug regulation in the
United States under section 505(j) of the
FD&C Act.
6. Applicant ANDA
Refused to file the letter
issued
Bioequivalence
Review
Chemistry/
Micro review
Request for
Plant inspection
Acceptance
and
completion
No
Yes
Review
by
OGD/CDER
Labelling Review
Bioequivalence
acceptance
Chemistry/
Micro review
No Approval
Letter
Bioequivalence
Deficiency
Letter
No
No
ANDA Flow chart
8. The Center for Drug Evaluation and Research is a division of the U.S. Food and Drug
Administration that monitors most drugs as defined in the Food, Drug, and Cosmetic Act.
Some biological products are also legally considered drugs, but they are covered by the
Center for Biologics Evaluation and Research.
GDUFA10 was signed into law to speed the delivery of safe and effective generic drugs to
the public and reduce costs to industry.
Office of generic drug (OGD) strongly encourages submission of bioequivalence, chemistry
and labeling portions of the application in electronic format.
This guidance details the information that should be provided in each section of the
common technical document (CTD) format for human pharmaceutical product
applications2 and identifies supporting guidance documents and recommendations issued
by FDA to assist applicants in preparing their ANDA submission.
9. CTD (Common Technical Document)
The CTD format was developed by the International Council for Harmonization of
Technical Requirements for Pharmaceuticals for Human Use (ICH) to streamline the
submission requirements for Japan, the European Union, and the United States.
The CTD is comprised of the following modules:
Module 1: Administrative Information
Module 2: Summaries
Module 3: Quality
Module 4: Nonclinical
Module 5: Clinical
10. Format of ANDA
3 copies of the Abbreviated application are required to be submitted; an
archival copy, a review copy and a field copy. An Archival copy shall contain
the following:
Application form
Table of Contents
Basis for ANDA submission
Conditions of use
Active Ingredients
Route of Administration
Dosage form and Strength
Bioequivalence and Bioavailability
11. Labeling
Chemistry, Manufacturing and Controls
Samples Patent Certification
Financial Certification or disclosure statement.
Other Information.
Under Section 314.94 (a) (12), the patent certification includes one of the
following: I. Paragraph I Certification- That the patent information has not
been submitted to FDA.
12. Under Section 314.94 (a) (12), the patent certification includes one of the following:
I. Paragraph I Certification- That the patent information has not been submitted
to FDA.
II. Paragraph II Certification- That the patent has expired
III. Paragraph III Certification- That the patent will expire (on date of marketing)
IV. Paragraph IV Certification- That the patent is invalid, unenforceable, or will
not be infringed by manufacture, use or sale of generic drug.
13. Difference between ANDA and NDA
➤NDA requires submission of:
1. Well-controlled clinical studies to demonstrate effectiveness.
2. Preclinical and clinical data to show safety.
3. Details of Manufacturing and Packaging.
4. Proposed annotated Labeling
➤ In contrast ANDA requires submission of:
1. Detailed description of components.
2. Manufacturing, Controls, Packaging, data to assure bioequivalence and
bioavailability and Labeling. Labeling should be prepared in accordance with DESI
(Drug efficacy study implementation).
14. EXCLUSIVITY
Exclusivity is a statutory provision designed to promote a balance between an
Innovator and Generic drug competitor. As long as a drug patent lasts, a reference
listed drug company enjoys a period of market exclusivity or monopoly. Expiration
of patent removes the monopoly of the patent holder.
TERMS OF EXCLUSIVITY
Orphan drugs---------- 7 years
New Chemical Entity----- -5 years
Pediatric Exclusivity---------6 months additional
Patent Challenge-180 days.